跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SPIKEVAX BIVALENT - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SPIKEVAX BIVALENT
Authorized
STANDARD
SPIKEVAX BIVALENT
moderna biopharma canada corporation
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
da551b0db20be045
Company
moderna biopharma canada corporation
Type
Standard
Approval Details
Approval Id
da551b0db20be045
Drug Approval Canada Name
SPIKEVAX BIVALENT
Product Name
SPIKEVAX BIVALENT
Status
Cancelled Post Market
Status Date
2024-01-19
Original Market Date
2022-09-12
Din
02530252
Drug Class
Human
Dosage Form
Dispersion
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BN01 COVID-19, RNA-BASED VACCINE
Atc Name
j 07 bn 01
Aig Number
0264021001
Company Name
moderna biopharma canada corporation
Company Address
3130, 155 Wellington Street West, Toronto, Ontario, Canada, M5V 3H1
Active Ingredients
ELASOMERAN
0.05 MG / ML
IMELASOMERAN
0.05 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
da551b0db20be045
Type
Standard
Back to Health Canada Approvals